|
Custodio, A; Carmona-Bayonas, A; Villabona, C; Perez, M; de La Cruz, G; Jimenez-Fonseca, P. On-going Evaluation of the Use of Resources and the Costs (UR/C) Associated with Controlled or Uncontrolled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine Tumors (NETs): RECOSY Study Design. NEUROENDOCRINOLOGY. 2018; 106:223-223.
AÑO: 2018; IF: 5.135
|
|
Owen GI, Pinto MP, Retamal IN, Fernádez MF, Cisternas B, Mondaca S, Sanchez C, Galindo H, Nervi B, Ibañez C, Acevedo F, Madrid J, Peña J, Bravo ML, Maturana MJ, Cordova-Delgado M, Romero D, de la Jara N, Torres J, Rodriguez-Fernandez M, Espinoza M, Balmaceda C, Freire M, Gárate-Calderón V, Crovari F, Jimenez-Fonseca P, Carmona-Bayonas A, Zwenger A, Armisen R, Corvalan AH, Garrido M. Chilean Gastric Cancer Task Force: A study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients. Medicine (Baltimore). 2018 Apr;97(16):e0419. doi: 10.1097/MD.0000000000010419. PubMed PMID: 29668600; PubMed Central PMCID: PMC5916646.
AÑO: 2018; IF: 1.87
|
|
Gallego, J; Reig, O; Sastre, J; Garcia, I; Segura, A; Capdevila, J; Carmona-Bayonas, A; Sevilla, I; Alonso, T; Crespo, G; de La Cruz, G; Benavent, M. Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study. NEUROENDOCRINOLOGY. 2018; 106:226-226.
AÑO: 2018; IF: 5.135
|
|
Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria I, Lacalle A, Visa L, Rodríguez Palomo A, Mangas M, Cano JM, Buxo E, Álvarez-Manceñido F, García T, Lorenzo JE, Ferrer-Cardona M, Viudez A, Azkarate A, Ramchandani A, Arias D, Longo F, López C, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Fernández Montes A, Sala P, Cerdá P, Rivera F, Gallego J; AGAMENON study group. Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric Cancer. 2018 Jan;21(1):96-105. doi: 10.1007/s10120-017-0718-5. Epub 2017 Apr 9. PubMed PMID: 28393278.
AÑO: 2018; IF: 5.554
|
|
Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, Jiménez-Fonseca P, Quintero G, Llorca C, Cañabate M, López LJ, Muñoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sanchez-Cánovas M, Gallego J, Guillén C, Ruiz-Miravet N, Navarro-Pérez V, De la Cámara J, Alés-Díaz I, Pazo-Cid RA, Carmona-Bayonas A. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer. 2018 Nov 29;18(1):1185. doi: 10.1186/s12885-018-5101-3. PubMed PMID: 30497432; PubMed Central PMCID: PMC6267080.
AÑO: 2018; IF: 2.933
|